Immunity in head and neck cancer

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Head and neck cancers encompass diverse malignancies, including those linked to viral infections, tobacco, and alcohol.
• Tumor development is closely linked to the host immune system, with endogenous antitumor responses potentially indicating prognosis.
• Current treatments like surgery, radiotherapy, and chemotherapy have limitations, including significant toxicities and poor response rates in certain patient subgroups.

Purpose of the Study:

• To explore the potential of tumor immunotherapy to improve treatment outcomes and reduce toxicity in head and neck cancers.
• To investigate the role of immune checkpoints and the efficacy of immune checkpoint inhibitors in virally mediated head and neck cancers.
• To evaluate biomarkers for predicting immunotherapy response regardless of viral status and to assess the benefits of immunotherapy in metastatic squamous cell carcinoma of the head and neck.

Main Methods:

• Review of ongoing studies evaluating immunotherapy in head and neck cancers.
• Exploration of therapeutic vaccines and adoptive therapy targeting virus-associated antigens.
• Investigation of immune checkpoint inhibitors for virally mediated cancers.
• Evaluation of biomarkers for immunotherapy response prediction.
• Analysis of combination therapies involving immunotherapy with chemotherapy and radiotherapy.

Main Results:

• Early promising results from immunotherapy studies in metastatic squamous cell carcinoma of the head and neck.
• Identification of virally mediated cancers as potential targets for preventive vaccines and therapeutic strategies.
• Active testing of immune checkpoint inhibitors, particularly for virally associated cancers.
• Evaluation of biomarkers to predict immunotherapy response across different cancer types.
• Intriguing prospects for synergistic benefits when combining immunotherapies with established treatments.

Conclusions:

• Immunotherapy holds significant potential to improve outcomes and reduce toxicity in head and neck cancer treatment.
• Virally mediated cancers offer unique targets for immunotherapy, including vaccines and checkpoint inhibitors.
• Further research is expanding immunotherapy applications to nonmetastatic diseases and other head and neck cancer types.
• Combination strategies involving immunotherapy and conventional treatments may offer synergistic advantages.